Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 3 out of 5

Results 1 - 9 of 9

Recs

1
Member Avatar Gibbs721 (35.29) Submitted: 2/6/2015 10:44:32 AM : Outperform Start Price: $85.01 BLUE Score: +28.81

Early results from attempts to cure hereditary diseases using genetic treatment look promising. Continued success would be a huge breakthrough with great potential for further developments and success.

Recs

0
Member Avatar MotleyFolJohn (< 20) Submitted: 2/2/2015 11:02:22 AM : Underperform Start Price: $93.98 BLUE Score: -14.02

The Bio Sector will out perform the 2015 NASDAQ However, BlueBird Bio will under perform.
Happy Investing

Recs

1
Member Avatar TMFInnovator (71.74) Submitted: 1/21/2015 12:03:16 PM : Outperform Start Price: $94.18 BLUE Score: +15.57

WOW - what a market opportunity!

Recs

1
Member Avatar NuclearSteve (70.11) Submitted: 1/7/2015 5:19:04 PM : Outperform Start Price: $97.90 BLUE Score: +11.48

Upside and chart eval

Recs

1
Member Avatar sullyz0r (81.44) Submitted: 11/26/2014 5:00:33 PM : Outperform Start Price: $42.49 BLUE Score: +162.70

Big fan of gene therapy.

Recs

1
Member Avatar SkepBioInvestor (96.20) Submitted: 6/26/2014 5:21:15 PM : Outperform Start Price: $39.88 BLUE Score: +173.48

Wall St darling

Recs

1
Member Avatar loangolfer (< 20) Submitted: 1/17/2014 8:43:56 AM : Outperform Start Price: $24.26 BLUE Score: +348.30

ZZ likes it......

Recs

10
Member Avatar zzlangerhans (99.82) Submitted: 8/22/2013 1:17:56 AM : Outperform Start Price: $27.03 BLUE Score: +288.35

There's some companies I study fairly vigorously before I start nattering about them and some I don't. Bluebird falls into the latter category. There's not much I can do - I'm just one guy trying to follow 250 stocks plus I have two babies who think Dad's laptop is the greatest toy in the world. All I can say about Bluebird is that they're developing lentoviral vectors, which I believe are the vectors you use when you've given up other viral vectors for Lent. Bluebird has one trial in progress for a lentoviral gene therapy of beta thalassemia and another planned to begin in mid-2013, and they're planning to initiate a phase II/III trial of another lentoviral gene therapy for childhood cerebral adrenoleukodystrophy in late 2013.

I happen to own 40 shares of Bluebird bought at the absolute all time high of 36 on July 17, courtesy of Portefeuille. I don't mean to razz him too much; that doesn't happen very often. The stock's been in a pretty nasty declining trend since then but I have a feeling things will pick back up before long. Hopefully by then I'll have had time to brush up a little on what this company actually does.

Recs

1
Member Avatar usubanas (99.74) Submitted: 8/21/2013 2:49:52 PM : Outperform Start Price: $25.51 BLUE Score: +313.07

the future is... here

Results 1 - 9 of 9

Featured Broker Partners


Advertisement